Precision BioSciences, Inc. (Nasdaq: DTIL) is a pre-clinical stage gene editing company developing in vivo gene editing with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly complex edits for gene insertion and/or gene repair. Precision BioSciences is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

Aliment Capital

The Longevity Fund

RA Capital Management

Leerink Partners

Ridgeback Capital

Alexandria Venture Investments

Cormorant Asset Management

Ditch Plains Capital Management LP

DUMAC

F-Prime Capital

Precision BioSciences, Inc.

Following pre-IND regulatory feedback from the FDA and ex-US regulators, we are advancing PBGENE-HBV toward an IND/CTA filing in 2024. 
 
The goal of our #investigational PBGENE-HBV program is to achieve a functional cure for patients with Chronic Hepatitis B. Hear from Chari Cohen, president of the Hepatitis B Foundation, on what this could mean for those living with HBV.
 
https://bit.ly/48fEVrt

How is ARCUS positioned to move beyond simple gene knockouts and tackle more sophisticated edits like gene elimination, excision, and insertion? 

Hear from Precision CRO, Jeff Smith in his #JPM2024 interview with pharmaphorum as they discuss the future of gene editing with ARCUS and going beyond CRISPR for in vivo gene editing.

Watch:
https://bit.ly/3TXFhQ4

Good news! We’ve completed a licensing deal with TG Therapeutics, Inc. to develop azer-cel for autoimmune diseases.

The deal extends our cash runway into the first half of 2026 and funds our wholly owned In vivo gene editing programs PBGENE-HBV for chronic hepatitis B and PBGENE-PMM for primary mitochondrial myopathy through Phase I Clinical Data.

Precision remains focused on capitalizing on the utility of ARCUS for gene elimination, gene excision and gene insertion through the advancement of our wholly owned and partnered programs.

Read more #JPM24: https://bit.ly/48IqY63

Precision CEO, Michael Amoroso, will speak at Longwood Healthcare Leaders in San Francisco on “The Future of Genetic Therapies” – joining other key industry thought leaders to discuss a wide range of issues affecting biopharma and healthcare. #longwoodhealthcareleaders

Learn more: https://bit.ly/3Tzx7gz

Precision’s Wendy Shoop, PhD., and University of Miami’s Carlos Moraes spoke with BioWorld about the recent publication in Nature Metabolism on mitoARCUS and our #investigational approach to primary mitochondrial myopathy. Read more from their conversation here: https://bit.ly/48g3Bk6

We’re pleased to announce the approval of the first clinical trial application of an ARCUS gene insertion program. Our partner iECURE received clearance from the Australian Therapeutic Goods Administration for a Phase 1/2 trial of ECUR-506, incorporating an ARCUS nuclease for the treatment of OTC deficiency. https://bit.ly/3NsrYDc

At this year’s Hep DART 2023, our Chief Research Officer and co-founder, Jeff Smith, & HBV Research Lead, Emily Harrison, presented on our #investigational PBGENE-HBV program. 

Learn more about our in vivo gene editing: https://bit.ly/41dIegX

We’re proud to share new research published in Nature Metabolism alongside Carlos Moraes that supports the development of mitoARCUS as an in vivo gene editing therapeutic for mitochondrial DNA diseases associated with the m.3243A>G mutation. Read more: https://bit.ly/3tcryK2.

In honor of #Thanksgiving tomorrow we want to thank all our employees for their dedication and celebrate our stakeholders for their investment and belief in Precision. It’s been an active year for us, and we’re looking forward to closing out the year strong.

We’re excited to share that we presented at the Sidoti & Company, LLC November Conference earlier today on our innovative ARCUS technology. ARCUS is capable of more sophisticated gene edits, with a focus on insertions, excisions and eliminations. That is the #ARCUS difference. See a recording of the presentation at the link below: https://bit.ly/3QZ4WWx

Domain Not Resolving

DNSSEC

Google Maps

Cloudflare CDN

Cloudflare Hosting

Cloudflare

Apple Mobile Web App Capable

Google Maps API

Ruby on Rails Token

Java EE

Healthcare

Alan List

Chief Financial Officer

Alex Kelly

Chief Business Officer

Cindy Atwell

General Counsel

Dario Scimeca

Chief Operating Officer

David Thomson

Chief Science Officer

Jeff Smith

Audit Chair

Melinda Brown

President & CEO

Michael Amoroso

Vice President, Accounting & Controller, Chief Accounting Officer

Shane Barton

Vice President, Gene Therapy Discovery

Cassie Gorsuch

Raymond F.Schinazi

Robert Adelman

Ben Auspitz

Matthew Kane

Shalini Sharp

Derek Jantz

Neil Leatherbury

Co-Founder & Chief Executive Officer

Co-Founder and Chief Scientific Officer

Co-Founder, Chief Technical Officer and Chief Science Officer

Naresh Tanna

Vice President of Investor Relations

Abid Ansari

Fayaz Khazi

President

Murray Abramson

SVP, Head of Clinical Development

Imugene is a publicly-listed biotechnology company with operations in America and Europe,

Health Care Companies With Less Than $500M in Revenue (Top 10K)

East Coast Companies With Less Than $50M in Revenue (Top 10K)

North Carolina Companies With Less Than $1B in Revenue (Top 10K)

Health Care Companies With Fewer Than 1000 Employees (Top 10K)

Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS.

Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.

Post-IPO Equity - Precision BioSciences

Debt Financing - Precision BioSciences

ArrowMark Partners

venBio Partners

Series B - Precision BioSciences

Series A - Precision BioSciences

Seed Round - Precision BioSciences

Computer and Software Services and Scientific Services

Durham

North Carolina

United States

North America

Precision BioSciences

Precision BioSciences to Participate in Upcoming November Investor Conferences

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Precision Biosciences files CTAs for PBGENE-HBV for chronic HBV

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences chief medical officer Alan List to retire

Precision BioSciences Receives $13M

Precision BioSciences to Participate in Upcoming August Investor Conferences

Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit

A genome editing platform that uses DNA-cutting enzymes for targeted modifications of DNA in living cells and tissues.

A proprietary genome editing platform using sequence-specific nucleases to modify DNA in living cells and tissues.

A facility dedicated to the production of advanced therapeutic products.

A gene editing program targeting chronic hepatitis B, aiming to eliminate the virus by editing its DNA.

Collaborations focused on utilizing ARCUS for gene editing directly inside the human body for therapeutic applications.

Partnerships aimed at developing CAR T-cell therapies, where T cells are genetically modified outside the body before being reintroduced to the patient.

Romania

Europe

Ukraine

HTML5

jQuery

GoDaddy Premium DNS

Google Tag Manager

Office 365

Modernizr

Bootstrap

Google Fonts

DigiCert

CRISPR Therapeutics is a biotechnology company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform.

CRISPR Therapeutics

Editas Medicine is a leading genome editing company that aims to translate its genome editing technology into a novel class of human therapeutics for the treatment of patients with genetically defined diseases.

Editas Medicine

Intellia Therapeutics is a leading genome editing company focused on the development of potentially curative therapeutics using the CRISPR/Cas9 system.

Intellia Therapeutics

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary 'ARCUS' genome editing platform.

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

news impact assignment basic	general	Mar 8, 2024 7:58 AM	c097e914
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 7:58 AM	ca33dfc6
company summary	general
signals	general	Mar 8, 2024 7:58 AM	7aebbdfa
crunchbase trigger	general	Nov 22, 2024 7:44 AM	25477969
crunchbase profile	general	Nov 22, 2024 9:31 AM	9d42fb23
li profile	general	Mar 8, 2024 7:58 AM	6721db96
translate crunchbase fundingrounds	general	Nov 22, 2024 1:53 PM	ab250bf5
peers	general	Mar 8, 2024 7:58 AM	a57b4579
news basic	general	Mar 8, 2024 7:58 AM	8a319018
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:PRECISIONBIOSCIENCES

Precision BioSciences, Inc.

Last Close

6.50

22/11 21:00

Market Cap

67.46M

Beta: -

Volume Today

105.61K

Avg: -